Literature DB >> 12736091

A new measure of dysconjugacy in INO: the first-pass amplitude.

Elliot M Frohman1, Padraig O'Suilleabhain, Richard B Dewey, Teresa C Frohman, Phillip D Kramer.   

Abstract

BACKGROUND: The ratios of abducting to adducting eye movements (versional dysconjugacy index, VDI) for saccadic velocity and acceleration have been useful measures by which to objectively characterize internuclear ophthalmoparesis (INO). Amplitude measures of dysconjugacy have been less useful, given that many patients maintain the ability to ultimately reach a centrifugal fixation target and that traditional amplitude measures of VDI have focused on this 'final amplitude' (FA) position.
METHODS: We utilized infrared oculography to define a new amplitude measure of dysconjugacy in 42 multiple sclerosis (MS) patients with INO. The first-pass amplitude (FPA)-VDI is the ratio of abduction/adduction eye movement amplitudes computed at the time when the abducting eye initially achieves the centrifugal horizontal fixation target.
RESULTS: FPA-VDI values were significantly more sensitive and specific than FA-VDI values in demonstrating dysconjugacy in INO, and there was a 14-fold increase in dysconjugacy as measured by FPA-VDI Z-scores when compared to FA-VDI Z-scores.
CONCLUSION: Consideration of velocity (pulse) and amplitude (step) components of dysconjugacy in patients with INO can provide a greater understanding of the dynamic aspects of this syndrome. We propose to characterize the relationship between the pathophysiology of INO and neuroradiologic measures of tissue injury in MS.

Entities:  

Mesh:

Year:  2003        PMID: 12736091     DOI: 10.1016/s0022-510x(03)00027-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  9 in total

1.  Visualisation of the medial longitudinal fasciculus using fibre tractography in multiple sclerosis patients with internuclear ophthalmoplegia.

Authors:  J P McNulty; R Lonergan; J Bannigan; R O'Laoide; L A Rainford; N Tubridy
Journal:  Ir J Med Sci       Date:  2016-01-19       Impact factor: 1.568

Review 2.  Uhthoff's phenomena in MS--clinical features and pathophysiology.

Authors:  Teresa C Frohman; Scott L Davis; Shin Beh; Benjamin M Greenberg; Gina Remington; Elliot M Frohman
Journal:  Nat Rev Neurol       Date:  2013-06-04       Impact factor: 42.937

3.  Neuro-ophthalmologic aspects of multiple sclerosis: Using eye movements as a clinical and experimental tool.

Authors:  Annette Niestroy; Janet C Rucker; R John Leigh
Journal:  Clin Ophthalmol       Date:  2007-09

4.  Using fast eye movements to study fatigue in multiple sclerosis.

Authors:  M Matta; R J Leigh; M Pugliatti; I Aiello; A Serra
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910

5.  Diagnosing disconjugate eye movements: phase-plane analysis of horizontal saccades.

Authors:  Alessandro Serra; Ke Liao; Manuela Matta; R John Leigh
Journal:  Neurology       Date:  2008-10-07       Impact factor: 9.910

6.  Eye disorders in patients with multiple sclerosis: natural history and management.

Authors:  Jennifer Graves; Laura J Balcer
Journal:  Clin Ophthalmol       Date:  2010-12-06

Review 7.  Eye Movement Abnormalities in Multiple Sclerosis: Pathogenesis, Modeling, and Treatment.

Authors:  Alessandro Serra; Clara G Chisari; Manuela Matta
Journal:  Front Neurol       Date:  2018-02-05       Impact factor: 4.003

8.  Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.

Authors:  Kawita M S Kanhai; Jenny A Nij Bijvank; Yorick L Wagenaar; Erica S Klaassen; KyoungSoo Lim; Sandrin C Bergheanu; Axel Petzold; Ajay Verma; Jacob Hesterman; Mike P Wattjes; Bernard M J Uitdehaag; Laurentius J van Rijn; Geert Jan Groeneveld
Journal:  CNS Neurosci Ther       Date:  2019-02-12       Impact factor: 5.243

9.  Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia.

Authors:  J A Nij Bijvank; L J van Rijn; L J Balk; H S Tan; B M J Uitdehaag; A Petzold
Journal:  Neurology       Date:  2019-04-19       Impact factor: 9.910

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.